Literature DB >> 35248201

Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease.

Roger L Albin1, Sygrid van der Zee2, Teus van Laar2, Martin Sarter3, Cindy Lustig3, Martijn L T M Muller4, Nicolaas I Bohnen5.   

Abstract

Dysfunction and degeneration of CNS cholinergic systems is a significant component of multi-system pathology in Parkinson's disease (PD). We review the basic architecture of human CNS cholinergic systems and the tools available for studying changes in human cholinergic systems. Earlier post-mortem studies implicated abnormalities of basal forebrain corticopetal cholinergic (BFCC) and pedunculopontine-laterodorsal tegmental (PPN-LDT) cholinergic projections in cognitive deficits and gait-balance deficits, respectively. Recent application of imaging methods, particularly molecular imaging, allowed more sophisticated correlation of clinical features with regional cholinergic deficits. BFCC projection deficits correlate with general and domain specific cognitive deficits, particularly for attentional and executive functions. Detailed analyses suggest that cholinergic deficits within the salience and cingulo-opercular task control networks, including both neocortical, thalamic, and striatal nodes, are a significant component of cognitive deficits in non-demented PD subjects. Both BFCC and PPN-LDT cholinergic projection systems, and striatal cholinergic interneuron (SChI), abnormalities are implicated in PD gait-balance disorders. In the context of experimental studies, these results indicate that disrupted attentional functions of BFCC and PPN-LDT cholinergic systems underlie impaired gait-balance functions. SChI dysfunction likely impairs intra-striatal integration of attentional and motor information. Thalamic and entorhinal cortex cholinergic deficits may impair multi-sensory integration. Overt degeneration of CNS systems may be preceded by increased activity of cholinergic neurons compensating for nigrostriatal dopaminergic deficits. Subsequent dysfunction and degeneration of cholinergic systems unmasks and exacerbates functional deficits secondary to dopaminergic denervation. Research on CNS cholinergic systems dysfunctions in PD requires a systems-level approach to understanding PD pathophysiology.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetylcholine; Attention; Basal forebrain; Cognition; Mild cognitive impairment; Pedunculopontine nucleus; Striatum

Mesh:

Substances:

Year:  2022        PMID: 35248201      PMCID: PMC8957710          DOI: 10.1016/bs.pbr.2022.01.011

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  100 in total

1.  Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease.

Authors:  Carine Karachi; David Grabli; Frédéric A Bernard; Dominique Tandé; Nicolas Wattiez; Hayat Belaid; Eric Bardinet; Annick Prigent; Hans-Peter Nothacker; Stéphane Hunot; Andreas Hartmann; Stéphane Lehéricy; Etienne C Hirsch; Chantal François
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

2.  Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

Authors:  Hélène Hall; Stefanie Reyes; Natalie Landeck; Chris Bye; Giampiero Leanza; Kay Double; Lachlan Thompson; Glenda Halliday; Deniz Kirik
Journal:  Brain       Date:  2014-07-24       Impact factor: 13.501

Review 3.  The cholinergic system in the cerebellum: from structure to function.

Authors:  Changzheng Zhang; Peiling Zhou; Tifei Yuan
Journal:  Rev Neurosci       Date:  2016-12-01       Impact factor: 4.353

4.  Gait-related cerebral alterations in patients with Parkinson's disease with freezing of gait.

Authors:  Anke H Snijders; Inge Leunissen; Maaike Bakker; Sebastiaan Overeem; Rick C Helmich; Bastiaan R Bloem; Ivan Toni
Journal:  Brain       Date:  2010-12-01       Impact factor: 13.501

5.  Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy.

Authors:  H Shinotoh; H Namba; M Yamaguchi; K Fukushi; S Nagatsuka; M Iyo; M Asahina; T Hattori; S Tanada; T Irie
Journal:  Ann Neurol       Date:  1999-07       Impact factor: 10.422

6.  The pedunculopontine nucleus in Parkinson's disease.

Authors:  R M Zweig; W R Jankel; J C Hedreen; R Mayeux; D L Price
Journal:  Ann Neurol       Date:  1989-07       Impact factor: 10.422

Review 7.  Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline.

Authors:  Elizabeth C Ballinger; Mala Ananth; David A Talmage; Lorna W Role
Journal:  Neuron       Date:  2016-09-21       Impact factor: 17.173

Review 8.  The Cellular Diversity of the Pedunculopontine Nucleus: Relevance to Behavior in Health and Aspects of Parkinson's Disease.

Authors:  Ilse S Pienaar; Anthony Vernon; Philip Winn
Journal:  Neuroscientist       Date:  2016-12-07       Impact factor: 7.519

9.  Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation.

Authors:  Aaron Kucinski; Giovanna Paolone; Marc Bradshaw; Roger L Albin; Martin Sarter
Journal:  J Neurosci       Date:  2013-10-16       Impact factor: 6.167

10.  In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.

Authors:  Michel J Grothe; Miguel A Labrador-Espinosa; Silvia Jesús; Daniel Macías-García; Astrid Adarmes-Gómez; Fátima Carrillo; Elena Iglesias Camacho; Pablo Franco-Rosado; Florinda Roldán Lora; Juan Francisco Martín-Rodríguez; Miquel Aguilar Barberá; Pau Pastor; Sonia Escalante Arroyo; Berta Solano Vila; Anna Cots Foraster; Javier Ruiz Martínez; Francisco Carrillo Padilla; Mercedes Pueyo Morlans; Isabel González Aramburu; Jon Infante Ceberio; Jorge Hernández Vara; Oriol de Fábregues-Boixar; Teresa de Deus Fonticoba; Berta Pascual-Sedano; Jaime Kulisevsky; Pablo Martínez-Martín; Diego Santos-García; Pablo Mir
Journal:  Parkinsonism Relat Disord       Date:  2021-05-31       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.